ファセンラ小児用日本市販後調査（PMS）

基本情報

NCT ID

NCT06427876

ステータス

募集中

試験のフェーズ

-

試験タイプ

観察

目標被験者数

40

治験依頼者名

AstraZeneca

概要

The purpose of the investigation is to confirm the followings under the post-marketing actual use of Fasenra® Subcutaneous Injection 30 mg / 10mg Syringe (hereinafter referred to as Fasenra). 1. Development of unexpected related AEs\* 2. To grasp development of related AEs\* in the real-world post-marketing setting. 3. Effectiveness (pulmonary function and asthma control) \* AEs investigator or MAH considers that there is a reasonable possibility that the experience may have been caused by the drug

対象疾患

依頼者（Sponsor）